Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 3 for:    aby-035 | psoriasis

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-035

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02690142
Recruitment Status : Completed
First Posted : February 24, 2016
Last Update Posted : March 2, 2018
Sponsor:
Collaborator:
Covance
Information provided by (Responsible Party):
Affibody

Brief Summary:
The purpose of this first-in-human study is to investigate the safety and tolerability of ABY-035 when administered intravenously and subcutaneously, to healthy volunteers and to psoriasis patients.

Condition or disease Intervention/treatment Phase
Psoriasis Healthy Subjects Drug: Placebo Drug: ABY-035 i.v. Drug: ABY-035 s.c. Phase 1

Detailed Description:

This first in human study with ABY-035 (a novel IL-17A inhibitor (interleukin 17A)) consists of four Parts. Part A consists of a single ascending intravenous dose study with 40 healthy volunteers divided into five dose cohorts. Each group consists of 8 subjects where 6 subjects will receive ABY-035 and 2 will receive placebo. The subjects will be followed for pharmacokinetic and safety assessments up to Day 95 after dosing.

Part B of the study consists of 6 healthy volunteers who will be given a single subcutaneous dose of ABY-035. The subjects will follow the same study visit schedule as Part A.

Part C of the study will include up to 12 moderate-to-severe psoriasis patients who each patient will be given a single intravenous dose of ABY-035. The patients will follow the same study visit schedule as Part A and B.

Part D of the study will include up to 18 psoriasis patients (mild, moderate or severe). Each patient will participate in 3 or 7 biweekly dosing occasions of subcutaneously administered ABY-035. Patients will be followed regularly for safety, efficacy and pharmacokinetics for 8 weeks post-final dose.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase I, Partially-randomised, Partially Double-blinded, Safety, Tolerability and Pharmacokinetic Study of ABY-035 in Healthy Subjects and Psoriasis Patients
Study Start Date : February 2016
Actual Primary Completion Date : January 10, 2018
Actual Study Completion Date : January 10, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: ABY-035 i.v.
Part A: SAD (single ascending dose) including five different dose cohorts. ABY-035 given as intravenous injections. 6 ABY-035 and 2 placebo in each cohort.
Drug: Placebo
Single dose i.v.

Drug: ABY-035 i.v.
Single dose i.v.

Experimental: ABY-035 s.c.
Part B: Bioavailability study where 6 subjects will receive ABY-035 as a single subcutaneous injection.
Drug: ABY-035 s.c.
Single dose s.c.

Experimental: ABY-035 i.v. in psoriasis patients
Part C: Up to 12 psoriasis patients will receive ABY-035 as a single intravenous injection.
Drug: ABY-035 i.v.
Single dose i.v.

Experimental: ABY-035 s.c. in psoriasis patients
Part D: Up to 18 patients will receive 3 or 7 biweekly doses of ABY-035 as s.c. injections
Drug: ABY-035 s.c.
Single dose s.c.




Primary Outcome Measures :
  1. Number of Participants With Abnormal Laboratory Values or other Adverse Events [ Time Frame: Follow-up visit (Day 141) ]
    Safety is monitored by Vital signs, 12-lead ECGs, urinalysis, hematology, clinical chemistry, coagulation, proinflammatory cytokines and CRP


Secondary Outcome Measures :
  1. AUC (Area Under the Concentration-time curve) of ABY-035 in healthy subjects and in patients with moderate-to-severe psoriasis through analysis of serum samples [ Time Frame: Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29, Day 30, Day 31, Day 32, Day 43, Day 57, Day 71, Day 85, Day 95, Day 113, Day 141 ]
  2. t1/2 (half-life) of ABY-035 in healthy subjects and in patients with moderate-to-severe psoriasis through analysis of serum samples [ Time Frame: Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29, Day 30, Day 31, Day 32, Day 43, Day 57, Day 71, Day 85, Day 95, Day 113, Day 141 ]
  3. Maximum serum concentration (Cmax) of ABY-035 in healthy subjects and in patients with moderate-to-severe psoriasis through analysis of serum samples [ Time Frame: Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29, Day 30, Day 31, Day 32, Day 43, Day 57, Day 71, Day 85, Day 95, Day 113, Day 141 ]
  4. Time of maximum observed plasma concentration of ABY-035 in healthy subjects and in patients with moderate-to-severe psoriasis through analysis of serum samples [ Time Frame: Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29, Day 30, Day 31, Day 32, Day 43, Day 57, Day 71, Day 85, Day 95, Day 113, Day 141 ]
  5. Time of last quantifiable plasma concentration of ABY-035 in healthy subjects and in patients with moderate-to-severe psoriasis through analysis of serum samples [ Time Frame: Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29, Day 30, Day 31, Day 32, Day 43, Day 57, Day 71, Day 85, Day 95, Day 113, Day 141 ]
  6. Mean Residence Time (MRT) of ABY-035 in healthy subjects and in patients with moderate-to-severe psoriasis through analysis of serum samples [ Time Frame: Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29, Day 30, Day 31, Day 32, Day 43, Day 57, Day 71, Day 85, Day 95, Day 113, Day 141 ]
  7. Total plasma clearance of ABY-035 in healthy subjects and in patients with moderate-to-severe psoriasis through analysis of serum samples [ Time Frame: Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29, Day 30, Day 31, Day 32, Day 43, Day 57, Day 71, Day 85, Day 95, Day 113, Day 141 ]
  8. Absolute bioavailability (F) of ABY-035 following a single subcutaneous administration in healthy subjects. [ Time Frame: Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29, Day 43, Day 71, Day 95 ]
    After single subcutaneous injection

  9. Time immediately prior to first quantifiable concentration of ABY-035 following a single subcutaneous administration in healthy subjects. [ Time Frame: Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29, Day 43, Day 71, Day 95 ]
    After single subcutaneous injection

  10. Volume of distribution during the terminal elimination phase of ABY-035 in healthy subjects and in patients with moderate-to-severe psoriasis through analysis of serum samples [ Time Frame: Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29, Day 30, Day 31, Day 32, Day 43, Day 57, Day 71, Day 85, Day 95, Day 113, Day 141 ]
  11. Volume of distribution at steady state of ABY-035 in healthy subjects and in patients with moderate-to-severe psoriasis through analysis of serum samples [ Time Frame: Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29, Day 30, Day 31, Day 32, Day 43, Day 57, Day 71, Day 85, Day 95, Day 113, Day 141 ]
  12. Clinical efficacy of ABY-035, using PASI (Psoriasis Area and Disease Index) response, following single dose intravenous administration in patients with moderate-to-severe psoriasis. [ Time Frame: Screening, Day -1, Day 2, Day 8, Day 15, Day 17, Day 22, Day 29, Day 31, Day 43, Day 71, Day 57, Day 85, Day 95, Day 113, Day 123, Day 141, Day 151 ]
  13. Immunogenicity of ABY-035 in healthy subjects and in patients with moderate-to-severe psoriasis [ Time Frame: Day -1, Day 1, Day 15, Day 29, Day 57, Day 85, Day 95, Day 113, Day 141 ]
    Measurement of the occurrence of anti-drug antibodies



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Part A, Part B

  • Males or females between 18 and 65 years of age
  • Body mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2, inclusive. maximum body weight of 120 kg
  • In good health, as determined by medical history, physical examination, vital signs assessment, 12 lead electrocardiogram (ECG) and clinical laboratory evaluations.
  • Subjects will have given their written informed consent to participate in the study

In addition for Part C and D

  • Males or females between 18 and 65 years of age
  • Body mass index (BMI) between 18.0 kg/m2 and 39.9 kg/m2, inclusive. Minimum body weight of 45 kg
  • Part C: Patients must have had a diagnosis of moderate to severe plaque type psoriasis at least 6 months prior to administration of the study drug without a documented flare within 30 days prior to Screening. Patients with concurrent psoriatic arthritis may be enrolled.
  • Part D: Patients must have had a diagnosis of plaque type psoriasis (mild, moderate or severe) at least 6 months prior to administration of the study drug without a documented flare within 30 days prior to Screening. Patients with concurrent psoriatic arthritis may be enrolled.
  • Part C: Have plaque type psoriasis covering at least 10% of total body surface area (BSA) at Screening and at Baseline (Day 1) and have a PASI score of 12 or greater at Screening and at Baseline (Day 1).
  • Part D: Have at least one psoriatic lesion

Exclusion criteria:

Part A, Part B, Part C and Part D

  • Subjects who have any clinically significant medical history, as determined by the investigator
  • Subjects who smoke more than 15 cigarettes, or equivalent, per day
  • Alcohol and/or drug abuse
  • Positive for HIV, Hepatitis B, Hepatitis C, or tuberculosis
  • Subjects who have received a live vaccination within the 3 months prior to Screening
  • Subjects who are pregnant or lactating
  • Subjects who do not agree to use appropriate contraception
  • Subjects who have a history of anaphylaxis, drug allergy or clinically significant allergic condition (excluding non active hayfever)
  • Participation in another clinical trial
  • Subjects who, in the opinion of the investigator, should not participate in this study

In addition for Part C and D

  • Patients who currently have non plaque forms of psoriasis (eg, erythrodermic, guttate, or pustular)
  • Patients who have current drug induced psoriasis
  • Have any history of any use of or have participated in clinical trials for any therapeutic agent directly targeted to any IL 17 cytokine or receptor
  • Have received phototherapy within 4 weeks prior to Day 1
  • Patients who have received systemic medications or treatments that could affect psoriasis or PASI evaluation (including, but not limited to, oral or injectable corticosteroids, retinoids, 1,25 dihydroxy vitamin D3 and analogues, fumaric acid esters, psoralens, anti TNF (tumour necrosis factor) biologics, anti IL 12/23 biologics, or herbal treatments), within 5 half lives prior to Day 1 (4 weeks for oral anti psoriatics, 12 weeks for psoralens and PUVA (oral psoralen with ultraviolet A), and 24 weeks for biologics)
  • Patients who have used topical medications and treatments that could affect psoriasis or PASI evaluation (eg, corticosteroids, coal tar, anthralin, calcipotriene, topical vitamin D derivatives, retinoids, tazarotene, methoxsalen, and trimethyl psoralens) within 2 weeks of administration of IMP (Investigational Medicinal Product)
  • Patients who have used any systemic immunosuppressants (eg, methotrexate, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, or tacrolimus) within 8 weeks of administration of IMP (or 5 half lives, whichever is longer).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02690142


Locations
Layout table for location information
United Kingdom
Covance Clinical Research Unit Ltd.
Leeds, United Kingdom, LS2 9LH
Covance and Royal Liverpool University Hospital Clinical Research Unit
Liverpool, United Kingdom, L7 8XP
Imperial Centre for Translational and Experimental Medicine Imperial College Healthcare NHS Trust Hammersmith Hospital
London, United Kingdom, W12 0HS
Medicines Evaluation Unit Ltd
Manchester, United Kingdom, M23 9QZ
Sponsors and Collaborators
Affibody
Covance
Investigators
Layout table for investigator information
Principal Investigator: Sunu Valasseri, MBBS, MSc Covance Ltd

Layout table for additonal information
Responsible Party: Affibody
ClinicalTrials.gov Identifier: NCT02690142     History of Changes
Other Study ID Numbers: ABY-035-001
2015-004531-13 ( EudraCT Number )
First Posted: February 24, 2016    Key Record Dates
Last Update Posted: March 2, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases